Merck Q3 Results - Q3 Top Pharma Company Earnings Reports

View Merck's Q3 Earnings Report

FiercePharma says: Merck posted better-than-expected profits, aided by a.) strong sales of its diabetes meds and HIV treatments; b.) a one-time $1.7 billion gain on the sale of its animal health business Merial; and c.) cost-cutting, particularly in marketing-and-administrative. Profits came in at $3.42 billion on a 2 percent growth in sales to $6.05 billion. Read more...


  • Third-Quarter 2009 Non-GAAP EPS Increases 13 Percent to $0.90, Excluding Certain Items; Reports Third-Quarter GAAP EPS of $1.61, Including Gain from Merial Sale
  • Continued Growth of Key Products, JANUVIA, JANUMET, ISENTRESS and SINGULAIR, Drives Strong Results
  • Merck Updates Full-Year 2009 Non-GAAP EPS Range to $3.20 to $3.30, Excluding Certain Items, and 2009 GAAP EPS Range to $3.69 to $3.89

Check out Merck's current earnings estimates from CNN Money

Merck's Website:

Merck Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.